Swiss Life Forecast, price target & analysts
Swiss Life Target price 2025 - Analyst rating & recommendation
Swiss Life Classifications & Recommendation:
Swiss Life Price Target
| Target Price | CHF770.50 |
| Price | CHF821.40 |
| Deviation | 6.20% |
| Number of Estimates | 14 |
| 14 Analysts have issued a price target Swiss Life 2026 . The average Swiss Life target price is CHF770.50. This is 6.20% lower than the current stock price. The highest price target is CHF900.00 9.57% , the lowest is CHF575.00 30.00% . | |
| A rating was issued by 16 analysts: 6 Analysts recommend Swiss Life to buy, 7 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Swiss Life stock has an average upside potential 2026 of 6.20% . Most analysts recommend the Swiss Life stock at Hold. |
Sales and Margin forecast 2025, 2026 to 2028
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion CHF | 10.92 | 18.42 |
| 16.63% | 68.79% | |
| Net Margin | 11.12% | 7.01% |
| 34.46% | 36.97% |
5 Analysts have issued a sales forecast Swiss Life 2025 . The average Swiss Life sales estimate is CHF18.4b . This is 68.79% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF21.2b 94.26% , the lowest is CHF8.9b 18.10% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | CHF10.9b | 16.63% |
|---|---|---|
| 2025 | CHF18.4b | 68.79% |
| 2026 | CHF18.8b | 2.20% |
| 2027 | CHF18.3b | 2.65% |
| 2028 | CHF22.4b | 22.41% |
9 Swiss Life Analysts have issued a net profit forecast 2025. The average Swiss Life net profit estimate is CHF1.3b . This is 6.37% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF1.4b 11.58% , the lowest is CHF1.2b 1.82% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | CHF1.2b | 12.10% |
|---|---|---|
| 2025 | CHF1.3b | 6.37% |
| 2026 | CHF1.4b | 6.91% |
| 2027 | CHF1.5b | 5.98% |
| 2028 | CHF1.6b | 9.38% |
Net Margin
| 2024 | 11.12% | 34.46% |
|---|---|---|
| 2025 | 7.01% | 36.97% |
| 2026 | 7.33% | 4.56% |
| 2027 | 7.98% | 8.87% |
| 2028 | 7.13% | 10.65% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 42.29 | 45.26 |
| 14.27% | 7.02% | |
| P/E | 18.15 | |
| EV/Sales | 1.77 |
9 Analysts have issued a Swiss Life forecast for earnings per share. The average Swiss Life EPS is CHF45.26 . This is 8.33% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF47.48 13.64% , the lowest is CHF43.33 3.71% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | CHF42.29 | 14.27% |
|---|---|---|
| 2025 | CHF45.26 | 7.02% |
| 2026 | CHF48.39 | 6.92% |
| 2027 | CHF51.28 | 5.97% |
| 2028 | CHF56.09 | 9.38% |
P/E ratio
| Current | 19.66 | 16.88% |
|---|---|---|
| 2025 | 18.15 | 7.68% |
| 2026 | 16.98 | 6.45% |
| 2027 | 16.02 | 5.65% |
| 2028 | 14.64 | 8.61% |
Based on analysts' sales estimates for 2025, the Swiss Life stock is valued at an EV/Sales of 1.77 and an P/S ratio of 1.26 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 2.99 | 69.89% |
|---|---|---|
| 2025 | 1.77 | 40.68% |
| 2026 | 1.74 | 2.15% |
| 2027 | 1.78 | 2.71% |
| 2028 | 1.46 | 18.30% |
P/S ratio
| Current | 2.13 | 49.91% |
|---|---|---|
| 2025 | 1.26 | 40.75% |
| 2026 | 1.24 | 2.15% |
| 2027 | 1.27 | 2.72% |
| 2028 | 1.04 | 18.31% |
Current Swiss Life Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Buy
➜
Buy
|
Unchanged | Mar 31 2025 |
| DAY BY DAY |
Buy
➜
Buy
|
Unchanged | Feb 05 2025 |
| BERENBERG |
Buy
➜
Buy
|
Unchanged | Dec 12 2024 |
| BNP PARIBAS EXANE |
Outperform
➜
Outperform
|
Unchanged | Dec 08 2024 |
| HSBC |
Hold
➜
Hold
|
Unchanged | Nov 24 2024 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
BERENBERG:
Buy
➜
Buy
|
Mar 31 2025 |
|
Unchanged
DAY BY DAY:
Buy
➜
Buy
|
Feb 05 2025 |
|
Unchanged
BERENBERG:
Buy
➜
Buy
|
Dec 12 2024 |
|
Unchanged
BNP PARIBAS EXANE:
Outperform
➜
Outperform
|
Dec 08 2024 |
|
Unchanged
HSBC:
Hold
➜
Hold
|
Nov 24 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
